The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from CNW Group

Cipher Pharmaceuticals to present at Biotech Showcase? 2013

Thursday, January 03, 2013

Cipher Pharmaceuticals to present at Biotech Showcase? 201309:00 EST Thursday, January 03, 2013Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, Jan. 3, 2013 /CNW/ -Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at Biotech Showcase™ 2013, which is being held in San Francisco at the Wyndham Parc 55 Hotel at Union Square. Mr. Andrews will provide a corporate update on Monday, January 7, 2013 at 1:45 PM PST in the Powell Room, followed immediately by Q&A breakout session in the Balboa Room.To learn more about Biotech Showcase™ 2013 please visit their website http://bit.ly/134dueyCipher's presentation will be available on their website www.cipherpharma.com.About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules. Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners. Cipher's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and in Canada as Durela®. Cipher's third product, a novel formulation of the acne treatment isotretinoin, was approved by the FDA in May and was launched in the United States in Q4 2012 as Absorica™. The product was also recently approved by Health Canada and Cipher expects to launch it as Epuris™ in Canada in Q2 2013.For more information, please visit www.cipherpharma.com.SOURCE: Cipher Pharmaceuticals Inc.For further information: Craig Armitage Investor Relations The Equicom Group (416) 815-0700 ext 278 (416) 815-0080 fax carmitage@equicomgroup.com Larry Andrews President and CEO Cipher Pharmaceuticals (905) 602-5840 ext 324 (905) 602-0628 fax landrews@cipherpharma.com